Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment is a research paper published in Acta Pharmaceutica Sinica B (2024). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Multiple Sclerosis Society
Grant: GR-1807-31630
National Institutes of Health
Grant: AI139535
NIAID NIH HHS
Grant: R21 AI185716
NINDS NIH HHS
Grant: T32 NS115664
NIAID NIH HHS
Grant: R01 AI139535
National Institutes of Health
Grant: 5R01AI139535-04
Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity
University of Utah
FWCI
1.16
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals